INTRODUCTION The therapeutic potential of a hemostatic agent can be assessed by investigating its effects on the quantitative parameters of thrombin generation. For recombinant activated factor VII (rFVIIa)--a promising hemostasis-inducing biologic--experimental studies addressing its effects on thrombin generation yielded disparate results. To elucidate the inherent ability of rFVIIa to modula...

Twenty five of 106 preterm infants of 34 weeks' gestation or less developed intraventricular haemorrhage within the first 48 hours of life. A comparison of infants with and without intraventricular haemorrhage showed no significant differences in their haemostatic parameters at birth. At age 48 hours the group with intraventricular haemorrhage showed a prolonged activated partial thromboplastin...

BACKGROUND Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. METHODS This single-center, descriptive, cross sectional study was carried out in Thrombus an...

It has long been known that the " prothrombin " time of a specimen of plasma to which has been added a brain extract thromboplastin depends on the presence of other factors in addition to prothrombin. Biggs, Douglas, and Macfarlane (1953) have demonstrated that both factor V and factor VII take part in a preliminary reaction with the brain extract to produce an activated thromboplastin. Hardist...

abstract  introduction: during extrinsic coagulation pathway, a complex is developed between factor vii, calcium and tissue factor (a cell membrane lipoprotein that is exposed after cell injury). factor vii needs calcium and vitamin k for its biologic activation. coronary artery disease (cad) can be induced by increased level and activity of the coagulation factors vii, viii and ix. in postmeno...